LOX-1 in atherosclerosis: Biological functions and pharmacological modifiers

Cellular and Molecular Life Sciences

Volumn 70, Issue 16, 2013, Pages 2859-2872

  Xu, Suowen ^a,b   Ogura, Sayoko ^c   Chen, Jiawei ^d   Little, Peter J ^e   Moss, Joel ^a   Liu, Peiqing ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

^c NIHON UNIVERSITY   (Japan)

^d FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^e RMIT UNIVERSITY   (Australia)

Author keywords

Atherosclerosis; LOX 1; Oxidized LDL; Review; Soluble LOX 1

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CIGLITAZONE; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DILTIAZEM; GELATINASE A; GELATINASE B; GLICLAZIDE; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; MESSENGER RNA; METFORMIN; MEVINOLIN; NITRIC OXIDE; OLMESARTAN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PRAVASTATIN; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; TANSHINONE IIA;

APOPTOSIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL ADHESION; CELL AGING; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSFORMATION; CHOLESTEROL TRANSPORT; DOWN REGULATION; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HUMAN; LOX 1 GENE; MACROPHAGE; MOLECULAR PATHOLOGY; MONOCYTE; NONHUMAN; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; THROMBOCYTE ACTIVATION;

ANIMALS; ATHEROSCLEROSIS; HUMANS; LIPOPROTEINS, LDL; SCAVENGER RECEPTORS, CLASS E;

EID: 84881159451     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-012-1194-z     Document Type: Review

References (114)

1. Ross R (1999) Atherosclerosis - an inflammatory disease. N Engl J Med 340(2):115-126
2. Little PJ, Osman N, O'Brien KD (2008) Hyperelongated biglycan: the surreptitious initiator of atherosclerosis. Curr Opin Lipidol 19(5):448-454
3. Burch ML, Zheng W, Little PJ (2011) Smad linker region phosphorylation in the regulation of extracellular matrix synthesis. Cell Mol Life Sci 68(1):97-107
4. Ballinger ML, Nigro J, Frontanilla KV, Dart AM, Little PJ (2004) Regulation of glycosaminoglycan structure and atherogenesis. Cell Mol Life Sci 61(11):1296-1306
5. Little PJ, Chait A, Bobik A (2011) Cellular and cytokine-based inflammatory processes as novel therapeutic targets for the prevention and treatment of atherosclerosis. Pharmacol Ther 131(3):255-268
6. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL (1989) Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320(14):915-924
7. Yamada Y, Doi T, Hamakubo T, Kodama T (1998) Scavenger receptor family proteins: roles for atherosclerosis, host defence and disorders of the central nervous system. Cell Mol Life Sci 54(7):628-640
8. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, Tanaka T, Miwa S, Katsura Y, Kita T, Masaki T (1997) An endothelial receptor for oxidized low-density lipoprotein. Nature 386(6620):73-77
9. Sawamura T, Kakino A, Fujita Y (2012) LOX-1: a multiligand receptor at the crossroads of response to danger signals. Curr Opin Lipidol 23(5):439-445
10. Draude G, Hrboticky N, Lorenz RL (1999) The expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-1) on human vascular smooth muscle cells and monocytes and its down-regulation by lovastatin. Biochem Pharmacol 57(4):383-386
11. Iwai-Kanai E, Hasegawa K, Sawamura T, Fujita M, Yanazume T, Toyokuni S, Adachi S, Kihara Y, Sasayama S (2001) Activation of lectin-like oxidized low-density lipoprotein receptor-1 induces apoptosis in cultured neonatal rat cardiac myocytes. Circulation 104(24):2948-2954
12. Hu C, Dandapat A, Sun L, Marwali MR, Inoue N, Sugawara F, Inoue K, Kawase Y, Jishage K, Suzuki H, Hermonat PL, Sawamura T, Mehta JL (2008) Modulation of angiotensin II-mediated hypertension and cardiac remodeling by lectin-like oxidized low-density lipoprotein receptor-1 deletion. Hypertension 52(3):556-562
13. Chui PC, Guan HP, Lehrke M, Lazar MA (2005) PPARgamma regulates adipocyte cholesterol metabolism via oxidized LDL receptor 1. J Clin Invest 115(8):2244-2256
14. Dieudonne A, Torres D, Blanchard S, Taront S, Jeannin P, Delneste Y, Pichavant M, Trottein F, Gosset P (2012) Scavenger receptors in human airway epithelial cells: role in response to double-stranded RNA. PLoS ONE 7(8):e41952
15. Parlato S, Romagnoli G, Spadaro F, Canini I, Sirabella P, Borghi P, Ramoni C, Filesi I, Biocca S, Gabriele L, Belardelli F (2010) LOX-1 as a natural IFN-alpha-mediated signal for apoptotic cell uptake and antigen presentation in dendritic cells. Blood 115(8):1554-1563
16. Chen M, Kakutani M, Naruko T, Ueda M, Narumiya S, Masaki T, Sawamura T (2001) Activation-dependent surface expression of LOX-1 in human platelets. Biochem Biophys Res Commun 282(1):153-158
17. Kataoka H, Kume N, Miyamoto S, Minami M, Moriwaki H, Murase T, Sawamura T, Masaki T, Hashimoto N, Kita T (1999) Expression of lectinlike oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation 99(24):3110-3117
18. Yoshimoto R, Fujita Y, Kakino A, Iwamoto S, Takaya T, Sawamura T (2011) The discovery of LOX-1, its ligands and clinical significance. Cardiovasc Drugs Ther 25(5):379-391
19. Xu S, Liu Z, Huang Y, Le K, Tang F, Huang H, Ogura S, Little P, Shen X, Liu P (2012) Tanshinone II-A inhibits oxidized LDL-induced LOX-1 expression in macrophages by reducing intracellular superoxide radical generation and NF-κB activation. Transl Res 160(2):114-124
20. Chen M, Masaki T, Sawamura T (2002) LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther 95(1):89-100
21. Pirillo A, Reduzzi A, Ferri N, Kuhn H, Corsini A, Catapano AL (2011) Upregulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) by 15-lipoxygenase-modified LDL in endothelial cells. Atherosclerosis 214(2):331-337
22. Shiu SW, Tan KC, Wong Y, Leng L, Bucala R (2009) Glycoxidized LDL increases lectin-like oxidized low-density lipoprotein receptor-1 in diabetes mellitus. Atherosclerosis 203(2):522-527
23. Ogura S, Kakino A, Sato Y, Fujita Y, Iwamoto S, Otsui K, Yoshimoto R, Sawamura T (2009) Lox-1: the multifunctional receptor underlying cardiovascular dysfunction. Circ J 73(11):1993-1999
24. Kume N, Kita T (2001) Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in atherogenesis. Trends Cardiovasc Med 11(1):22-25
25. Qian Y, Zhang X, Zhou L, Yun X, Xie J, Xu J, Ruan Y, Ren S (2012) Site-specific N-glycosylation identification of recombinant human lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1). Glycoconj J 29(5-6):399-409
26. Inoue K, Arai Y, Kurihara H, Kita T, Sawamura T (2005) Overexpression of lectin-like oxidized low-density lipoprotein receptor-1 induces intramyocardial vasculopathy in apolipoprotein E-null mice. Circ Res 97(2):176-184
27. White SJ, Sala-Newby GB, Newby AC (2011) Overexpression of scavenger receptor LOX-1 in endothelial cells promotes atherogenesis in the ApoE(-/-) mouse model. Cardiovasc Pathol 20(6):369-373
28. Mehta JL, Sanada N, Hu CP, Chen J, Dandapat A, Sugawara F, Satoh H, Inoue K, Kawase Y, Jishage K, Suzuki H, Takeya M, Schnackenberg L, Beger R, Hermonat PL, Thomas M, Sawamura T (2007) Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res 100(11):1634-1642
29. Ishigaki Y, Katagiri H, Gao J, Yamada T, Imai J, Uno K, Hasegawa Y, Kaneko K, Ogihara T, Ishihara H, Sato Y, Takikawa K, Nishimichi N, Matsuda H, Sawamura T, Oka Y (2008) Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis. Circulation 118(1):75-83
30. Li H, Meininger CJ, Hawker JR Jr, Haynes TE, Kepka-Lenhart D, Mistry SK, Morris SM Jr, Wu G (2001) Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab 280(1):E75-E82
31. Ryoo S, Bhunia A, Chang F, Shoukas A, Berkowitz DE, Romer LH (2011) OxLDL-dependent activation of arginase II is dependent on the LOX-1 receptor and downstream RhoA signaling. Atherosclerosis 214(2):279-287
32. Shi Y, Cosentino F, Camici GG, Akhmedov A, Vanhoutte PM, Tanner FC, Luscher TF (2011) Oxidized low-density lipoprotein activates p66Shc via lectin-like oxidized low-density lipoprotein receptor-1, protein kinase C-beta, and c-Jun N-terminal kinase kinase in human endothelial cells. Arterioscler Thromb Vasc Biol 31(9):2090-2097
33. Xu X, Gao X, Potter BJ, Cao JM, Zhang C (2007) Anti-LOX-1 rescues endothelial function in coronary arterioles in atherosclerotic ApoE knockout mice. Arterioscler Thromb Vasc Biol 27(4):871-877
34. Eichhorn B, Muller G, Leuner A, Sawamura T, Ravens U, Morawietz H (2009) Impaired vascular function in small resistance arteries of LOX-1 overexpressing mice on high-fat diet. Cardiovasc Res 82(3):493-502
35. Sugimoto K, Ishibashi T, Sawamura T, Inoue N, Kamioka M, Uekita H, Ohkawara H, Sakamoto T, Sakamoto N, Okamoto Y, Takuwa Y, Kakino A, Fujita Y, Tanaka T, Teramoto T, Maruyama Y, Takeishi Y (2009) LOX-1-MT1-MMP axis is crucial for RhoA and Rac1 activation induced by oxidized low-density lipoprotein in endothelial cells. Cardiovasc Res 84(1):127-136
36. Besler C, Heinrich K, Rohrer L, Doerries C, Riwanto M, Shih DM, Chroni A, Yonekawa K, Stein S, Schaefer N, Mueller M, Akhmedov A, Daniil G, Manes C, Templin C, Wyss C, Maier W, Tanner FC, Matter CM, Corti R, Furlong C, Lusis AJ, von Eckardstein A, Fogelman AM, Luscher TF, Landmesser U (2011) Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 121(7):2693-2708
37. Braunersreuther V, Mach F (2006) Leukocyte recruitment in atherosclerosis: potential targets for therapeutic approaches? Cell Mol Life Sci 63(18):2079-2088
38. Li D, Mehta JL (2000) Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation 101(25):2889-2895
39. Honjo M, Nakamura K, Yamashiro K, Kiryu J, Tanihara H, McEvoy LM, Honda Y, Butcher EC, Masaki T, Sawamura T (2003) Lectin-like oxidized LDL receptor-1 is a cell-adhesion molecule involved in endotoxin-induced inflammation. Proc Natl Acad Sci USA 100(3):1274-1279
40. Chen JW, Zhou SB, Tan ZM (2010) Aspirin and pravastatin reduce lectin-like oxidized low-density lipoprotein receptor-1 expression, adhesion molecules and oxidative stress in human coronary artery endothelial cells. Chin Med J (Engl) 123(12):1553-1556
41. Li DY, Chen HJ, Mehta JL (2001) Statins inhibit oxidized-LDL-mediated LOX-1 expression, uptake of oxidized-LDL and reduction in PKB phosphorylation. Cardiovasc Res 52(1):130-135
42. Chen J, Mehta JL, Haider N, Zhang X, Narula J, Li D (2004) Role of caspases in Ox-LDL-induced apoptotic cascade in human coronary artery endothelial cells. Circ Res 94(3):370-376
43. Li D, Mehta JL (2009) Intracellular signaling of LOX-1 in endothelial cell apoptosis. Circ Res 104(5):566-568
44. Lu J, Yang JH, Burns AR, Chen HH, Tang D, Walterscheid JP, Suzuki S, Yang CY, Sawamura T, Chen CH (2009) Mediation of electronegative low-density lipoprotein signaling by LOX-1: a possible mechanism of endothelial apoptosis. Circ Res 104(5):619-627
45. Khaidakov M, Wang X, Mehta JL (2011) Potential involvement of LOX-1 in functional consequences of endothelial senescence. PLoS ONE 6(6):e20964
46. Eto H, Miyata M, Kume N, Minami M, Itabe H, Orihara K, Hamasaki S, Biro S, Otsuji Y, Kita T, Tei C (2006) Expression of lectin-like oxidized LDL receptor-1 in smooth muscle cells after vascular injury. Biochem Biophys Res Commun 341(2):591-598
47. Hinagata J, Kakutani M, Fujii T, Naruko T, Inoue N, Fujita Y, Mehta JL, Ueda M, Sawamura T (2006) Oxidized LDL receptor LOX-1 is involved in neointimal hyperplasia after balloon arterial injury in a rat model. Cardiovasc Res 69(1):263-271
48. Hu C, Dandapat A, Sun L, Chen J, Marwali MR, Romeo F, Sawamura T, Mehta JL (2008) LOX-1 deletion decreases collagen accumulation in atherosclerotic plaque in low-density lipoprotein receptor knockout mice fed a high-cholesterol diet. Cardiovasc Res 79(2):287-293
49. Moriwaki H, Kume N, Kataoka H, Murase T, Nishi E, Sawamura T, Masaki T, Kita T (1998) Expression of lectin-like oxidized low-density lipoprotein receptor-1 in human and murine macrophages: upregulated expression by TNF-alpha. FEBS Lett 440(1-2):29-32
50. Yoshida H, Kondratenko N, Green S, Steinberg D, Quehenberger O (1998) Identification of the lectin-like receptor for oxidized low-density lipoprotein in human macrophages and its potential role as a scavenger receptor. Biochem J 334:9-13
51. Schaeffer DF, Riazy M, Parhar KS, Chen JH, Duronio V, Sawamura T, Steinbrecher UP (2009) LOX-1 augments oxLDL uptake by lysoPC-stimulated murine macrophages but is not required for oxLDL clearance from plasma. J Lipid Res 50(8):1676-1684
52. Ishiyama J, Taguchi R, Yamamoto A, Murakami K (2010) Palmitic acid enhances lectin-like oxidized LDL receptor (LOX-1) expression and promotes uptake of oxidized LDL in macrophage cells. Atherosclerosis 209(1):118-124
53. Li L, Sawamura T, Renier G (2004) Glucose enhances human macrophage LOX-1 expression: role for LOX-1 in glucose-induced macrophage foam cell formation. Circ Res 94(7):892-901
54. Li D, Liu L, Chen H, Sawamura T, Ranganathan S, Mehta JL (2003) LOX-1 mediates oxidized low-density lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells. Circulation 107(4):612-617
55. Li L, Renier G (2009) The oral anti-diabetic agent, gliclazide, inhibits oxidized LDL-mediated LOX-1 expression, metalloproteinase-9 secretion and apoptosis in human aortic endothelial cells. Atherosclerosis 204(1):40-46
56. Clarke MC, Figg N, Maguire JJ, Davenport AP, Goddard M, Littlewood TD, Bennett MR (2006) Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med 12(9):1075-1080
57. Hsieh CC, Yen MH, Yen CH, Lau YT (2001) Oxidized low-density lipoprotein induces apoptosis via generation of reactive oxygen species in vascular smooth muscle cells. Cardiovasc Res 49(1):135-145
58. Kume N, Kita T (2004) Apoptosis of vascular cells by oxidized LDL: involvement of caspases and LOX-1 and its implication in atherosclerotic plaque rupture. Circ Res 94(3):269-270
59. Kataoka H, Kume N, Miyamoto S, Minami M, Morimoto M, Hayashida K, Hashimoto N, Kita T (2001) Oxidized LDL modulates Bax/Bcl-2 through the lectinlike Ox-LDL receptor-1 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 21(6):955-960
60. Hu C, Dandapat A, Sun L, Khan JA, Liu Y, Hermonat PL, Mehta JL (2008) Regulation of TGFbeta1-mediated collagen formation by LOX-1: studies based on forced overexpression of TGFbeta1 in wild-type and lox-1 knock-out mouse cardiac fibroblasts. J Biol Chem 283(16):10226-10231
61. Marwali MR, Hu CP, Mohandas B, Dandapat A, Deonikar P, Chen J, Cawich I, Sawamura T, Kavdia M, Mehta JL (2007) Modulation of ADP-induced platelet activation by aspirin and pravastatin: role of lectin-like oxidized low-density lipoprotein receptor-1, nitric oxide, oxidative stress, and inside-out integrin signaling. J Pharmacol Exp Ther 322(3):1324-1332
62. Kakutani M, Masaki T, Sawamura T (2000) A platelet-endothelium interaction mediated by lectin-like oxidized low-density lipoprotein receptor-1. Proc Natl Acad Sci USA 97(1):360-364
63. Sakurai K, Cominacini L, Garbin U, Fratta Pasini A, Sasaki N, Takuwa Y, Masaki T, Sawamura T (2004) Induction of endothelin-1 production in endothelial cells via co-operative action between CD40 and lectin-like oxidized LDL receptor (LOX-1). J Cardiovasc Pharmacol 44(Suppl 1):S173-S180
64. Cominacini L, Fratta Pasini A, Garbin U, Pastorino A, Rigoni A, Nava C, Davoli A, Lo Cascio V, Sawamura T (2003) The platelet-endothelium interaction mediated by lectin-like oxidized low-density lipoprotein receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells. J Am Coll Cardiol 41(3):499-507
65. Tanigawa H, Miura S, Matsuo Y, Fujino M, Sawamura T, Saku K (2006) Dominant-negative lox-1 blocks homodimerization of wild-type lox-1-induced cell proliferation through extracellular signal regulated kinase 1/2 activation. Hypertension 48(2):294-300
66. Li D, Yang B, Mehta JL (1998) Ox-LDL induces apoptosis in human coronary artery endothelial cells: role of PKC, PTK, bcl-2, and Fas. Am J Physiol 275(2 Pt 2):H568-H576
67. Sun Y, Chen X (2011) Ox-LDL-induced LOX-1 expression in vascular smooth muscle cells: role of reactive oxygen species. Fundam Clin Pharmacol 25(5):572-579
68. Stein S, Lohmann C, Schafer N, Hofmann J, Rohrer L, Besler C, Rothgiesser KM, Becher B, Hottiger MO, Boren J, McBurney MW, Landmesser U, Luscher TF, Matter CM (2010) SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis. Eur Heart J 31(18):2301-2309
69. Thum T, Borlak J (2008) LOX-1 receptor blockade abrogates oxLDL-induced oxidative DNA damage and prevents activation of the transcriptional repressor Oct-1 in human coronary arterial endothelium. J Biol Chem 283(28):19456-19464
70. Chen J, Liu Y, Liu H, Hermonat PL, Mehta JL (2006) Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) transcriptional regulation by Oct-1 in human endothelial cells: implications for atherosclerosis. Biochem J 393:255-265
71. Li L, Sawamura T, Renier G (2003) Glucose enhances endothelial LOX-1 expression: role for LOX-1 in glucose-induced human monocyte adhesion to endothelium. Diabetes 52(7):1843-1850
72. Khaidakov M, Mitra S, Kang BY, Wang X, Kadlubar S, Novelli G, Raj V, Winters M, Carter WC, Mehta JL (2011) Oxidized LDL receptor 1 (OLR1) as a possible link between obesity, dyslipidemia and cancer. PLoS ONE 6(5):e20277
73. Cominacini L, Rigoni A, Pasini AF, Garbin U, Davoli A, Campagnola M, Pastorino AM, Lo Cascio V, Sawamura T (2001) The binding of oxidized low-density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide. J Biol Chem 276(17):13750-13755
74. Cominacini L, Pasini AF, Garbin U, Davoli A, Tosetti ML, Campagnola M, Rigoni A, Pastorino AM, Lo Cascio V, Sawamura T (2000) Oxidized low-density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species. J Biol Chem 275(17):12633-12638
75. Nagase M, Abe J, Takahashi K, Ando J, Hirose S, Fujita T (1998) Genomic organization and regulation of expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-1) gene. J Biol Chem 273(50):33702-33707
76. Li D, Saldeen T, Romeo F, Mehta JL (2000) Oxidized LDL upregulates angiotensin II type 1 receptor expression in cultured human coronary artery endothelial cells: the potential role of transcription factor NF-kappaB. Circulation 102(16):1970-1976
77. Li DY, Zhang YC, Philips MI, Sawamura T, Mehta JL (1999) Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circ Res 84(9):1043-1049
78. Li D, Singh RM, Liu L, Chen H, Singh BM, Kazzaz N, Mehta JL (2003) Oxidized-LDL through LOX-1 increases the expression of angiotensin converting enzyme in human coronary artery endothelial cells. Cardiovasc Res 57(1):238-243
79. Chen J, Liu Y, Liu H, Hermonat PL, Mehta JL (2006) Molecular dissection of angiotensin II-activated human LOX-1 promoter. Arterioscler Thromb Vasc Biol 26(5):1163-1168
80. Shiu SW, Wong Y, Tan KC (2012) Effect of advanced glycation end products on lectin-like oxidized low-density lipoprotein receptor-1 expression in endothelial cells. J Atheroscler Thromb. http://dx.doi.org/10.5551/jat.11742
81. Murase T, Kume N, Kataoka H, Minami M, Sawamura T, Masaki T, Kita T (2000) Identification of soluble forms of lectin-like oxidized LDL receptor-1. Arterioscler Thromb Vasc Biol 20(3):715-720
82. Mitsuoka H, Kume N, Hayashida K, Inui-Hayashiada A, Aramaki Y, Toyohara M, Jinnai T, Nishi E, Kita T (2009) Interleukin 18 stimulates release of soluble lectin-like oxidized LDL receptor-1 (sLOX-1). Atherosclerosis 202(1):176-182
83. Zhao XQ, Zhang MW, Wang F, Zhao YX, Li JJ, Wang XP, Bu PL, Yang JM, Liu XL, Zhang MX, Gao F, Zhang C, Zhang Y (2011) CRP enhances soluble LOX-1 release from macrophages by activating TNF-alpha converting enzyme. J Lipid Res 52(5):923-933
84. Lubrano V, Del Turco S, Nicolini G, Di Cecco P, Basta G (2008) Circulating levels of lectin-like oxidized low-density lipoprotein receptor-1 are associated with inflammatory markers. Lipids 43(10):945-950
85. Brinkley TE, Kume N, Mitsuoka H, Brown MD, Phares DA, Ferrell RE, Kita T, Hagberg JM (2008) Variation in the human lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1) gene is associated with plasma soluble LOX-1 levels. Exp Physiol 93(9):1085-1090
86. Hayashida K, Kume N, Murase T, Minami M, Nakagawa D, Inada T, Tanaka M, Ueda A, Kominami G, Kambara H, Kimura T, Kita T (2005) Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: a novel marker for early diagnosis. Circulation 112(6):812-818
87. Kume N, Mitsuoka H, Hayashida K, Tanaka M, Kita T (2010) Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts prognosis after acute coronary syndrome - a pilot study. Circ J 74(7):1399-1404
88. Kume N, Mitsuoka H, Hayashida K, Tanaka M, Kominami G, Kita T (2010) Soluble lectin-like oxidized LDL receptor-1 (sLOX-1) as a sensitive and specific biomarker for acute coronary syndrome-comparison with other biomarkers. J Cardiol 56(2):159-165
89. Inoue N, Okamura T, Kokubo Y, Fujita Y, Sato Y, Nakanishi M, Yanagida K, Kakino A, Iwamoto S, Watanabe M, Ogura S, Otsui K, Matsuda H, Uchida K, Yoshimoto R, Sawamura T (2010) LOX index, a novel predictive biochemical marker for coronary heart disease and stroke. Clin Chem 56(4):550-558
90. Uchida K, Suehiro A, Nakanishi M, Sawamura T, Wakabayashi I (2011) Associations of atherosclerotic risk factors with oxidized low-density lipoprotein evaluated by LOX-1 ligand activity in healthy men. Clin Chim Acta 412(17-18):1643-1647
91. Matsumoto T, Fujita M, Sawamura T, Kakino A, Sato Y, Fujita Y, Matsuda H, Nakanishi M, Uchida K, Nakae I, Kanda H, Yoshida A, Miwa K, Hayashi H, Mitsunami K, Horie M (2010) Pitavastatin reduces lectin-like oxidized low-density lipoprotein receptor-1 ligands in hypercholesterolemic humans. Lipids 45(4):329-335
92. Chen XP, Zhang TT, Du GH (2007) Lectin-like oxidized low-density lipoprotein receptor-1, a new promising target for the therapy of atherosclerosis? Cardiovasc Drug Rev 25(2):146-161
93. Mehta JL, Khaidakov M, Hermonat PL, Mitra S, Wang X, Novelli G, Sawamura T (2011) LOX-1: a new target for therapy for cardiovascular diseases. Cardiovasc Drugs Ther 25(5):495-500
94. Lu J, Mitra S, Wang X, Khaidakov M, Mehta JL (2011) Oxidative stress and lectin-like ox-LDL-receptor LOX-1 in atherogenesis and tumorigenesis. Antioxid Redox Signal 15(8):2301-2333
95. Mehta JL, Chen J, Hermonat PL, Romeo F, Novelli G (2006) Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovasc Res 69(1):36-45
96. Steinberg D, Witztum JL (2002) Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation 105(17):2107-2111
97. Kang BY, Khan JA, Ryu S, Shekhar R, Seung KB, Mehta JL (2010) Curcumin reduces angiotensin II-mediated cardiomyocyte growth via LOX-1 inhibition. J Cardiovasc Pharmacol 55(2):176-183
98. Guan S, Wang B, Li W, Guan J, Fang X (2010) Effects of berberine on expression of LOX-1 and SR-BI in human macrophage-derived foam cells induced by ox-LDL. Am J Chin Med 38(6):1161-1169
99. Huang Z, Dong F, Li S, Chu M, Zhou H, Lu Z, Huang W (2012) Berberine-induced inhibition of adipocyte enhancer-binding protein 1 attenuates oxidized low-density lipoprotein accumulation and foam cell formation in phorbol 12-myristate 13-acetate-induced macrophages. Eur J Pharmacol 690(1-3):164-169
100. Ou HC, Song TY, Yeh YC, Huang CY, Yang SF, Chiu TH, Tsai KL, Chen KL, Wu YJ, Tsai CS, Chang LY, Kuo WW, Lee SD (2010) EGCG protects against oxidized LDL-induced endothelial dysfunction by inhibiting LOX-1-mediated signaling. J Appl Physiol 108(6):1745-1756
101. Chang HC, Chen TG, Tai YT, Chen TL, Chiu WT, Chen RM (2011) Resveratrol attenuates oxidized LDL-evoked Lox-1 signaling and consequently protects against apoptotic insults to cerebrovascular endothelial cells. J Cereb Blood Flow Metab 31(3):842-854
102. Gao S, Liu Z, Li H, Little PJ, Liu P, Xu S (2012) Cardiovascular actions and therapeutic potential of tanshinone IIA. Atherosclerosis 220(1):3-10
103. Xu S, Little PJ, Lan T, Huang Y, Le K, Wu X, Shen X, Huang H, Cai Y, Tang F, Wang H, Liu P (2011) Tanshinone II-A attenuates and stabilizes atherosclerotic plaques in apolipoprotein-E knockout mice fed a high cholesterol diet. Arch Biochem Biophys 515(1-2):72-79
104. Hofnagel O, Luechtenborg B, Eschert H, Weissen-Plenz G, Severs NJ, Robenek H (2006) Pravastatin inhibits expression of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in Watanabe heritable hyperlipidemic rabbits: a new pleiotropic effect of statins. Arterioscler Thromb Vasc Biol 26(3):604-610
105. Kang BY, Wang W, Palade P, Sharma SG, Mehta JL (2009) Cardiac hypertrophy during hypercholesterolemia and its amelioration with rosuvastatin and amlodipine. J Cardiovasc Pharmacol 54(4):327-334
106. Matarazzo S, Quitadamo MC, Mango R, Ciccone S, Novelli G, Biocca S (2012) Cholesterol-lowering drugs inhibit LOX-1 receptor function by membrane raft disruption. Mol Pharmacol 82(2):246-254
107. Sugano M, Tsuchida K, Makino N (2002) Nifedipine prevents apoptosis of endothelial cells induced by oxidized low-density lipoproteins. J Cardiovasc Pharmacol 40(1):146-152
108. Zhou MS, Jaimes EA, Raij L (2004) Inhibition of oxidative stress and improvement of endothelial function by amlodipine in angiotensin II-infused rats. Am J Hypertens 17(2):167-171
109. Rudijanto A (2010) Calcium channel blocker (diltiazem) inhibits apoptosis of vascular smooth muscle cell exposed to high glucose concentration through lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) pathway. Acta Med Indones 42(2):59-65
110. Zhang H, Ma G, Yao Y, Qian H, Li W, Chen X, Jiang W, Zheng R (2012) Olmesartan attenuates the impairment of endothelial cells induced by oxidized low-density lipoprotein through downregulating expression of LOX-1. Int J Mol Sci 13(2):1512-1523
111. Mehta JL, Chen J, Yu F, Li DY (2004) Aspirin inhibits ox-LDL-mediated LOX-1 expression and metalloproteinase-1 in human coronary endothelial cells. Cardiovasc Res 64(2):243-249
112. Li D, Mehta JL (2000) Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors. Arterioscler Thromb Vasc Biol 20(4):1116-1122
113. Ouslimani N, Mahrouf M, Peynet J, Bonnefont-Rousselot D, Cosson C, Legrand A, Beaudeux JL (2007) Metformin reduces endothelial cell expression of both the receptor for advanced glycation end products and lectin-like oxidized receptor 1. Metabolism 56(3):308-313
114. Chiba Y, Ogita T, Ando K, Fujita T (2001) PPARgamma ligands inhibit TNF-alpha-induced LOX-1 expression in cultured endothelial cells. Biochem Biophys Res Commun 286(3):541-546